These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 9532377)

  • 1. [Certain biological properties of mutant human tumor necrosis factor-alpha].
    Sandakhchiev LS; Merzlikin NV; Pustoshilova NM; Istomina NN; Lebedev LR; Sviatchenko MI; Danilenko ED; Masycheva VI; Usova SV
    Biull Eksp Biol Med; 1998 Jan; 125(1):89-92. PubMed ID: 9532377
    [No Abstract]   [Full Text] [Related]  

  • 2. Biological activities of human tumor necrosis factor-alpha and its novel mutants.
    Xi T; Shi X; Guo D; Dong X; Xu X; Zhu D
    Biochem Mol Biol Int; 1996 May; 38(6):1183-9. PubMed ID: 8739040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal site-specific PEGylation of mutant TNF-alpha improves its antitumor potency.
    Yoshioka Y; Tsutsumi Y; Ikemizu S; Yamamoto Y; Shibata H; Nishibata T; Mukai Y; Okamoto T; Taniai M; Kawamura M; Abe Y; Nakagawa S; Nagata S; Yamagata Y; Mayumi T
    Biochem Biophys Res Commun; 2004 Mar; 315(4):808-14. PubMed ID: 14985084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Inhibitory effect of tumor necrosis factor and interferon with chemotherapeutic drugs on the growth of cancer cell of tongue].
    Qu XR; Shen ZH; He ZM
    Hunan Yi Ke Da Xue Xue Bao; 2000 Aug; 25(4):421-2. PubMed ID: 12206026
    [No Abstract]   [Full Text] [Related]  

  • 5. A novel human tumor necrosis factor alpha mutant showed potent antitumor activity and reduced toxicity in vivo.
    Lu F; Chen ZM; Liu QH; Chen CQ
    Acta Pharmacol Sin; 2001 Jul; 22(7):619-23. PubMed ID: 11749826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucocorticoid cotreatment induces apoptosis resistance toward cancer therapy in carcinomas.
    Herr I; Ucur E; Herzer K; Okouoyo S; Ridder R; Krammer PH; von Knebel Doeberitz M; Debatin KM
    Cancer Res; 2003 Jun; 63(12):3112-20. PubMed ID: 12810637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-human hepatocellular carcinoma effects of tumor necrosis factor-related apoptosis-inducing ligand in vitro & in vivo.
    Guo BC; Xu YH
    Acta Pharmacol Sin; 2001 Sep; 22(9):831-6. PubMed ID: 11749866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression and antitumor effects of TRAIL in human cholangiocarcinoma.
    Tanaka S; Sugimachi K; Shirabe K; Shimada M; Wands JR
    Hepatology; 2000 Sep; 32(3):523-7. PubMed ID: 10960444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha.
    Halin C; Gafner V; Villani ME; Borsi L; Berndt A; Kosmehl H; Zardi L; Neri D
    Cancer Res; 2003 Jun; 63(12):3202-10. PubMed ID: 12810649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo tumor targeting of tumor necrosis factor-alpha-loaded stealth nanoparticles: effect of MePEG molecular weight and particle size.
    Fang C; Shi B; Pei YY; Hong MH; Wu J; Chen HZ
    Eur J Pharm Sci; 2006 Jan; 27(1):27-36. PubMed ID: 16150582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of tumor necrosis factor-alpha with sulindac augments its apoptotic potential and suppresses tumor growth of human carcinoma cells in nude mice.
    Yasui H; Adachi M; Imai K
    Cancer; 2003 Mar; 97(6):1412-20. PubMed ID: 12627504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor necrosis factor.
    Oettgen HF; Old LJ
    Important Adv Oncol; 1987; ():105-30. PubMed ID: 2841229
    [No Abstract]   [Full Text] [Related]  

  • 13. PEGylated recombinant human tumor necrosis factor alpha: preparation and anti-tumor potency.
    Li YP; Pei YY; Ding J; Shen ZM; Zhang XY; Gu ZH; Zhou JJ
    Acta Pharmacol Sin; 2001 Jun; 22(6):549-55. PubMed ID: 11747763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytotoxic and antitumor activity of a recombinant tumor necrosis factor-B1(Fv) fusion protein on LeY antigen-expressing human cancer cells.
    Scherf U; Benhar I; Webber KO; Pastan I; Brinkmann U
    Clin Cancer Res; 1996 Sep; 2(9):1523-31. PubMed ID: 9816329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of tumor necrosis factor alpha in hyperthermia-induced apoptosis of human leukemia cells.
    Katschinski DM; Robins HI; Schad M; Frede S; Fandrey J
    Cancer Res; 1999 Jul; 59(14):3404-10. PubMed ID: 10416602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vitamin E succinate is a potent novel antineoplastic agent with high selectivity and cooperativity with tumor necrosis factor-related apoptosis-inducing ligand (Apo2 ligand) in vivo.
    Weber T; Lu M; Andera L; Lahm H; Gellert N; Fariss MW; Korinek V; Sattler W; Ucker DS; Terman A; Schröder A; Erl W; Brunk UT; Coffey RJ; Weber C; Neuzil J
    Clin Cancer Res; 2002 Mar; 8(3):863-9. PubMed ID: 11895920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety.
    Kelley SK; Harris LA; Xie D; Deforge L; Totpal K; Bussiere J; Fox JA
    J Pharmacol Exp Ther; 2001 Oct; 299(1):31-8. PubMed ID: 11561060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel human tumor necrosis factor alfa mutein, F4614, inhibits in vitro and in vivo growth of murine and human hepatoma: implication for immunotherapy of human hepatocellular carcinoma.
    Atarashi Y; Yasumura S; Nambu S; Yoshio Y; Murakami J; Takahara T; Higuchi K; Watanabe A; Miyata K; Kato M
    Hepatology; 1998 Jul; 28(1):57-67. PubMed ID: 9657097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A mutated human tumor necrosis factor-alpha improves the therapeutic index in vitro and in vivo.
    Yan Z; Zhao N; Wang Z; Li B; Bao C; Shi J; Han W; Zhang Y
    Cytotherapy; 2006; 8(4):415-23. PubMed ID: 16923618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transgene expression of alpha tumor necrosis factor with mutations D142N and A144R under control of human telomerase reverse transcriptase promoter eradicates well-established tumors and induces long-term antitumor immunity.
    Xiang J; Munegowda MA; Deng Y
    Cancer Gene Ther; 2009 May; 16(5):430-8. PubMed ID: 19096444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.